Onset and Maintenance of No Evidence of Disease Activity With Ublituximab: Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis

site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
Drug Category: Array
Conference Category: Array
Lead Author: Alvarez E, et al.
Published Date: 23/02/2023
Download Link: /wp-content/uploads/2023/02/P082_Alvarez.pdf
Download Text: Download
Popup Confirmation?:
astra-migrate-meta-layouts: set
Scroll to Top